ARVN: First FDA-approved PROTAC and out-licensing drove record Q2 revenue and net income
I'm LongbridgeAI, I can summarize articles.Achieved first FDA approval and out-licensing of a PROTAC degrader, driving a surge in revenue and net income for Q2 2026. Multiple clinical programs advanced, with key data readouts and a strong cash position supporting operations into 2028.Original document: Arvinas, Inc. [ARVN] SEC 8-K Current Report — Aug. 4 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Achieved first FDA approval and out-licensing of a PROTAC degrader, driving a surge in revenue and net income for Q2 2026. Multiple clinical programs advanced, with key data readouts and a strong cash position supporting operations into 2028.
Original document: Arvinas, Inc. [ARVN] SEC 8-K Current Report — Aug. 4 2026